Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) is an indication for drug development with over 140 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) have a 66.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) overview
Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite, and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infections with the Epstein-Barr virus (EBV) or HIV increase risk compared to the general population. Treatment includes surgery, radiation therapy, and chemotherapy.
For a complete picture of PTSR and LoA scores for drugs in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
